Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Head & Neck 1Gynecologic 1Gastrointestinal 1Breast 1

Conditions

Head and Neck Neoplasms 2Triple Negative Breast Neoplasms 1Thyroid Cancer, Papillary 1Stomach Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Pancreatic Neoplasms 1Ovarian Neoplasms 1Colorectal Neoplasms 1Carcinoma, Medullary 1

Interventions

pembrolizumab 23Nivolumab 10Trastuzumab 7Gemcitabine 6Cisplatin 6Cetuximab 6Docetaxel 5spartalizumab 4atezolizumab 4Ipilimumab 4Drug Therapy 4Cyclophosphamide 4Carboplatin 4Capecitabine 4palbociclib 3fludarabine 3cemiplimab 3Radiotherapy 3Magnetic Resonance Spectroscopy 3Erlotinib Hydrochloride 3Bortezomib 3ulixertinib 2trametinib 2sargramostim 2pertuzumab 2avelumab 2amminedichloro(2-methylpyridine)platinum(II) 2aldesleukin 2Taxes 2TH 302 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Pancreatic Neoplasms × Ferrosoferric Oxide × Head & Neck × Clear all
NCT01770353 2019-11-27

MM-398 (Nanoliposomal Irinotecan, Nal-IRI) to Determine Tumor Drug Levels and to Evaluate the Feasibility of Ferumoxytol Magnetic Resonance Imaging to Measure Tumor Associated Macrophages and to Predict Patient Response to Treatment

Ipsen

Phase 1 Completed
45 enrolled 33 charts
BreastGastrointestinalGynecologicHead & Neck

Head and Neck Neoplasms, Ovarian Neoplasms, Pancreatic Neoplasms, Stomach Neoplasms, Colorectal Neoplasms, Triple Negative Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡